Taisho Pharmaceutical Co., Ltd.

Nissan Chemical Industries Limited

Shoichi Kuroda

Yoshinori Sekiguchi

Hajime Asanuma

Yusuke Oka

Fumito Uneuchi

Naoya Ono

Nagaaki Sato

Hirofumi Ota

Takahiro Oi

Tetsuya Yabuuchi

Tetsuo Takayama

Tomomichi Chonan

Takumi Okada

Shigetada Sasako

Yudai Imai

Keiko Fusegi

Masahiro Bohno

Shin Itoh

Seishi Ishiyama

Takanori Kawaguchi

Yuji Ito

Hiroshi Ohta

Tsuyoshi Shibata

Shigeru Tokita

Fumihito Ushiyama

Keishi Hayashi

Yasunobu Ushiki

Madoka Kawamura

Takeshi Koami

Yuki Kobayashi

Kenichi Kawabe

Daisuke Wakasugi

Yoshihisa Shirasaki

Noriko Saito

Hideaki Tabuse

Souichi Monma

Rie Nishikawa

Kengo Watatani

Rui Jibiki

Kanako Hatanaka

Marie Mizutani

Yuko Uehara

Eiji Munetomo

Sumi Chonan

The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.

Urea compound for antagonizing LPA1 receptor

The present invention provides a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof which has an excellent NHE3 inhibitory effect:A-Y&#x2003;&#x2003;[1]wherein  

Phenyl tetrahydroisoquinoline compound substituted with heteroaryl

This 2-pyridone compound represented by formula [1] or a tautomer of said compound, or a pharmaceutically acceptable salt of said compound or said tautomer, or a solvate of said compound or the like has a superior GK-activating effect and is useful as a pharmaceutical. 

2-pyridone compound

Provided are novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof, as well as new therapeutics useful in the prevention or treatment of alopecia which comprise those compounds or pharmaceutically acceptable salts thereof. Specifically, compounds represented by formula (1) [where Rrepresents either the following formula (2) or (3)] or pharmaceutically acceptable salts thereof are provided.

Azole derivative

A 2-pyridone compound represented by the formula [1]: {wherein in the formula [1],the ring represented by A represents a benzene ring or a pyridine ring,X represents any of the structures represented by the formulas [3] shown below: V represents a single bond or a lower alkylene group, andW represents a single bond, an ether bond or a lower alkylene group (wherein the lower alkylene group may contain an ether bond)},a tautomer or stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof is a compound that has an excellent GK activating effect and is useful as a pharmaceutical.

2-pyridone compounds

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase &#x3b3; inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

Aminothiazole derivative

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.

Isoquinoline derivative

Growing community of inventors

Tokyo, Japan

Shoichi Kuroda